Importantly, he also kept the firm from falling behind on innovation, which we saw in the launch of the Rosa robot and stocking the pipeline with such devices as the Persona IQ smart knee, digital tools for surgeons and patients, and a redesigned cementless knee. We began to see green shoots in the second half of 2019, before the pandemic disrupted everything. Zimmer Biomet again saw accelerating top-line growth this year, and new management intends to maintain that trend while ramping up efforts to improve margins. Considering the existing strategy seems to be working, we think it's more likely that new management will tinker around the periphery rather than introduce any wholesale changes. With that in mind, we wouldn't be surprised to see Zimmer Biomet make more acquisitions in orthopedic-adjacent markets now that the balance sheet has regained strength.